Rapt Therapeutics (NASDAQ:RAPT) Receives $41.20 Average Target Price from Analysts

Shares of Rapt Therapeutics (NASDAQ:RAPT) have received an average rating of “Moderate Buy” from the thirteen research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation, six have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $41.20.

RAPT has been the topic of several analyst reports. UBS Group set a $9.00 price objective on shares of Rapt Therapeutics and gave the company a “neutral” rating in a report on Tuesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Rapt Therapeutics in a report on Wednesday, October 8th. Zacks Research lowered shares of Rapt Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, August 22nd. Lifesci Capital upgraded shares of Rapt Therapeutics to a “strong-buy” rating and set a $31.00 price objective on the stock in a report on Tuesday, July 22nd. Finally, Barclays increased their price objective on shares of Rapt Therapeutics from $35.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, October 21st.

Institutional Investors Weigh In On Rapt Therapeutics

Several large investors have recently bought and sold shares of the company. Callan Family Office LLC increased its stake in Rapt Therapeutics by 53.9% in the first quarter. Callan Family Office LLC now owns 89,327 shares of the company’s stock valued at $109,000 after purchasing an additional 31,287 shares in the last quarter. Comerica Bank increased its stake in Rapt Therapeutics by 53.9% in the first quarter. Comerica Bank now owns 89,327 shares of the company’s stock valued at $109,000 after purchasing an additional 31,287 shares in the last quarter. Invesco Ltd. increased its stake in Rapt Therapeutics by 411.7% in the first quarter. Invesco Ltd. now owns 58,901 shares of the company’s stock valued at $72,000 after purchasing an additional 47,391 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Rapt Therapeutics by 112.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 150,946 shares of the company’s stock valued at $184,000 after purchasing an additional 79,967 shares in the last quarter. Finally, Checkpoint Capital L.P. bought a new stake in Rapt Therapeutics in the first quarter valued at approximately $134,000. Institutional investors own 99.09% of the company’s stock.

Rapt Therapeutics Trading Up 1.7%

Shares of RAPT stock opened at $30.21 on Friday. Rapt Therapeutics has a 1 year low of $5.67 and a 1 year high of $42.39. The firm’s 50 day moving average is $22.53 and its 200-day moving average is $13.63. The firm has a market capitalization of $499.67 million, a price-to-earnings ratio of -2.13 and a beta of 0.20.

Rapt Therapeutics (NASDAQ:RAPT) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.04). On average, equities research analysts forecast that Rapt Therapeutics will post -2.14 earnings per share for the current fiscal year.

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.